Detalhe da pesquisa
1.
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
J Clin Immunol
; 41(6): 1146-1153, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33983545
2.
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Blood Adv
; 8(5): 1116-1127, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38163318
3.
CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
Semin Hematol
; 60(5): 329-337, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38336529
4.
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
Blood Adv
; 7(10): 2105-2116, 2023 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516084
5.
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.
Blood Adv
; 6(8): 2520-2534, 2022 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35244681
6.
SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection.
Front Immunol
; 12: 793197, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35116027
7.
Central Pontine Myelinolysis in Pediatric Diabetic Ketoacidosis.
Case Rep Crit Care
; 2018: 4273971, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29973999
8.
Optimal Line and Tube Placement in Very Preterm Neonates: An Audit of Practice.
Children (Basel)
; 4(11)2017 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-29149032